title: [Effect of pregnancy, menopause and hormone substitution therapy on disseminated systemic lupus erythematosus].
abstract: EXACERBATIONS DURING PREGNANCY: Clinical and experimental data have clearly evidenced the influence of hormones on the course of systemic lupus erythematosus. In prospective studies of pregnant women, an exacerbation is observed in 57% to 60% of the cases. It can be severe in 10% of the cases and occur in the post partum in 7%. For most patients, the exacerbation is moderate and has no unfavorable effect on the outcome of pregnancy. In case of renal involvement, it is difficult to differentiate an intricated HELPP syndrome.
  Low complement and elevated anti-DNA levels are distinctive markers. Earlier renal involvement and hypertension are important prognostic factors, particularly when the lupus begins during pregnancy. However, when serum creatinine is lower than 100 mumol/l at pregnancy onset in patients in remission, pregnancy does not alter renal function. An association with antiphospholipid antibodies increases the risk for the fetus and the kidney function.
  
  
  METHODS
  Optimal treatment remains to be defined. Commonly, patients are given aspirin, heparin in case of a history of thromboembolism, or both. The rate of success currently exceeds 70%. The risk of thromboembolism in the peri or post partum period requires anticoagulant treatment. Outside pregnancy: Ovulation induction raises two risks: triggering a lupus flare-up and thrombosis, particularly for patients with antiphospholipid antibodies. The influence of menopause and hormone replacement therapy remains poorly understood.
authors.affiliation: Service de Médecine interne, Groupe Hospitalier Pitié-Salpêtrière, Paris.
authors.forename: D
authors.initials: D
authors.lastname: Le Thi Huong
authors.forename: B
authors.initials: B
authors.lastname: Wechsler
authors.forename: J C
authors.initials: JC
authors.lastname: Piette
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000503:physiopathology; D010062:Ovulation Induction / Q000009:adverse effects; D011247:Pregnancy; D011248:Pregnancy Complications; D011256:Pregnancy Outcome; D011446:Prospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D006493:Heparin; D001241:Aspirin